https://larvol.hashnode.dev 2026-10-09T13:48:01.484Z always 1.0 https://larvol.hashnode.dev/efficacy-and-safety-of-relugolix-in-advanced-prostate-cancer-subgroup-analysis-of-concomitant-therapies-from-the-hero-study 2024-09-27T08:28:11.379Z daily 0.8 https://larvol.hashnode.dev/enhancing-psa-screening-recommendations-the-impact-of-color-coding-and-shared-decision-making-in-a-diverse-patient-population 2024-09-27T08:25:39.577Z daily 0.8 https://larvol.hashnode.dev/overcoming-platelet-induced-resistance-and-enhancing-anti-invasive-activity 2024-09-27T08:23:18.292Z daily 0.8 https://larvol.hashnode.dev/study-overview-combination-of-ftdtpi-with-iri-in-advanced-gastric-and-esophagogastric-junction-cancer-agec 2024-09-27T08:22:03.903Z daily 0.8 https://larvol.hashnode.dev/inclusion-and-exclusion-criteria-for-peripheral-t-cell-lymphoma-study 2024-09-27T08:20:53.844Z daily 0.8 https://larvol.hashnode.dev/phase-iii-study-of-mk-6482-vs-everolimus-in-advanced-clear-cell-renal-cell-carcinoma-study-design-and-objectives 2024-09-27T08:19:00.563Z daily 0.8 https://larvol.hashnode.dev/gilteritinib-plus-azacitidine-for-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia-phase-3-study-design-and-preliminary-results 2024-09-27T08:16:26.323Z daily 0.8 https://larvol.hashnode.dev/insights-from-a-multicenter-study-of-intensive-treatment-outcomes 2024-09-27T08:15:03.026Z daily 0.8 https://larvol.hashnode.dev/understanding-distress-in-advanced-cancer-patients-a-qualitative-analysis-of-the-p-cocc-values 2024-09-27T08:13:22.138Z daily 0.8 https://larvol.hashnode.dev/efficacy-and-safety-of-atezo-plus-pegph20-in-patients-with-metastatic-pdac-and-advanced-gastric-cancer 2024-09-27T08:11:38.429Z daily 0.8 https://larvol.hashnode.dev/initial-results-of-chemoablation-with-ugn-101-for-low-grade-upper-tract-urothelial-carcinoma 2024-09-27T08:09:08.674Z daily 0.8 https://larvol.hashnode.dev/long-term-survival-outcomes-of-multi-agent-chemotherapy-combined-with-sbrt-in-locally-advanced-pancreatic-cancer 2024-09-27T08:07:52.522Z daily 0.8 https://larvol.hashnode.dev/insights-from-a-phase-i-study-of-a-novel-anti-pd-1-monoclonal-antibody-in-solid-tumors 2024-09-27T08:06:05.982Z daily 0.8 https://larvol.hashnode.dev/outcomes-of-lenvatinib-in-patients-with-unresectable-hepatocellular-carcinoma-and-deteriorating-liver-function 2024-09-27T08:03:29.212Z daily 0.8 https://larvol.hashnode.dev/associations-between-health-related-quality-of-life-and-biological-markers-in-metastatic-castrate-resistant-prostate-cancer 2024-09-27T08:01:44.530Z daily 0.8 https://larvol.hashnode.dev/single-cell-dna-sequencing-reveals-clonal-dynamics-in-flt3-mutated-acute-myeloid-leukemia-during-crenolanib-combination-therapy 2024-09-20T11:15:26.961Z daily 0.8 https://larvol.hashnode.dev/phase-3-trial-of-gilteritinib-plus-azacitidine-vs-azacitidine-alone-in-newly-diagnosed-flt3-mutated-acute-myeloid-leukemia 2024-09-20T11:14:22.695Z daily 0.8 https://larvol.hashnode.dev/reassessing-the-prognostic-impact-of-ptpn11-mutations-in-acute-myeloid-leukemia 2024-09-20T11:12:39.647Z daily 0.8 https://larvol.hashnode.dev/a-qualitative-analysis-of-values-interviews-in-advanced-gastrointestinal-cancer 2024-09-20T11:11:22.458Z daily 0.8 https://larvol.hashnode.dev/efficacy-and-safety-of-atezo-pegph20-in-patients-with-metastatic-pancreatic 2024-09-20T11:10:27.660Z daily 0.8 https://larvol.hashnode.dev/chemoablation-with-prolonged-release-mitomycin-for-low-grade-upper-tract-urothelial-carcinoma 2024-09-20T11:09:32.457Z daily 0.8 https://larvol.hashnode.dev/a-phase-i-study-of-a-novel-anti-pd-1-monoclonal-antibody 2024-09-20T11:08:28.558Z daily 0.8 https://larvol.hashnode.dev/efficacy-of-lenvatinib-in-unresectable-hepatocellular-carcinoma 2024-09-20T11:07:13.657Z daily 0.8 https://larvol.hashnode.dev/erlotinib-and-proton-therapy-for-locally-advanced-pancreatic-cancer-a-phase-ii-trial 2024-09-20T10:00:30.995Z daily 0.8 https://larvol.hashnode.dev/linking-health-related-quality-of-life-and-biomarkers-in-metastatic-castrate-resistant-prostate-cancer 2024-09-20T09:59:39.051Z daily 0.8 https://larvol.hashnode.dev/link-between-health-related-quality-of-life-and-biomarkers-in-mcrpc-patients-cou-aa-301-trial-results 2024-09-20T09:58:32.894Z daily 0.8 https://larvol.hashnode.dev/sparc-1-a-phase-i-trial-of-neoadjuvant-il-1beta-and-pd-1-blockade-in-localized-renal-cell-carcinoma 2024-09-20T09:57:30.777Z daily 0.8 https://larvol.hashnode.dev/long-term-survival-of-sbrt-combined-with-multi-agent-chemotherapy-in-locally-advanced-pancreatic-cancer 2024-09-20T09:55:56.235Z daily 0.8 https://larvol.hashnode.dev/impact-of-endocrine-therapy-timing-on-disease-free-survival-in-breast-cancer-insights-from-the-unirad-phase-iii-trial-1 2024-09-20T09:54:24.372Z daily 0.8 https://larvol.hashnode.dev/phase-iii-study-of-mk-6482-vs-everolimus-in-advanced-clear-cell-renal-cell-carcinoma 2024-09-20T09:52:37.420Z daily 0.8 https://larvol.hashnode.dev/phase-ii-study-of-epcor-alone-vs-epcor-r2-consolidation-after-anti-cd19-car-t-cell-therapy-in-mrd-positive-lymphoma 2024-09-13T09:50:02.848Z daily 0.8 https://larvol.hashnode.dev/phase-iii-trial-of-liposomal-daunorubicin-and-su5416-for-hematologic-cancers-refractory-to-initial-therapy 2024-09-13T09:48:15.729Z daily 0.8 https://larvol.hashnode.dev/phase-ii-study-of-sbrt-for-oligoprogressive-mrcc-patients-after-first-line-systemic-therapy 2024-09-13T09:46:44.438Z daily 0.8 https://larvol.hashnode.dev/thalidomide-vs-dexamethasone-maintenance-after-stem-cell-transplant-for-multiple-myeloma 2024-09-13T09:46:02.694Z daily 0.8 https://larvol.hashnode.dev/phase-i-trial-of-cbm588-with-nivolumab-and-ipilimumab-for-advanced-kidney-cancer 2024-09-13T09:45:07.773Z daily 0.8 https://larvol.hashnode.dev/phase-ib-study-of-neoadjuvant-hfrt-with-pembrolizumab-and-chemotherapy-in-stage-iii-nsclc 2024-09-13T09:44:19.168Z daily 0.8 https://larvol.hashnode.dev/opioid-free-vs-conventional-anaesthesia-in-breast-cancer-surgery-a-randomized-trial 2024-09-13T09:43:29.397Z daily 0.8 https://larvol.hashnode.dev/phase-i-study-of-nk042-for-safety-and-efficacy-in-treating-malignant-ascites-from-gynecologic-cancer 2024-09-13T09:42:50.090Z daily 0.8 https://larvol.hashnode.dev/phase-i-study-to-evaluate-safety-tolerability-and-preliminary-efficacy-of-hemay181-in-patients-with-advanced-solid-tumors 2024-09-13T09:41:44.980Z daily 0.8 https://larvol.hashnode.dev/impact-of-endocrine-therapy-timing-on-disease-free-survival-in-breast-cancer-insights-from-the-unirad-phase-iii-trial 2024-09-13T09:40:36.119Z daily 0.8 https://larvol.hashnode.dev/enasidenib-shows-greater-survival-benefit-in-idh2-r172-variant-patients-with-relapsedrefractory-aml 2024-09-13T09:38:34.679Z daily 0.8 https://larvol.hashnode.dev/factors-associated-with-failure-to-undergo-resection-after-neoadjuvant-therapy-in-potentially-resectable-pancreatic-cancer 2024-09-13T09:37:40.709Z daily 0.8 https://larvol.hashnode.dev/olaparib-fails-to-improve-outcomes-in-brca12-wild-type-triple-negative-breast-cancer 2024-09-13T09:36:54.899Z daily 0.8 https://larvol.hashnode.dev/daratumumab-with-vcd-improves-outcomes-in-transplant-ineligible-myeloma-patients 2024-09-13T09:34:05.291Z daily 0.8 https://larvol.hashnode.dev/sequential-dosing-of-sacituzumab-govitecan-and-talazoparib-in-metastatic-tnbc-a-feasible-strategy 2024-09-13T09:32:48.852Z daily 0.8 https://larvol.hashnode.dev/comparing-symptom-monitoring-approaches-for-ambulatory-cancer-surgery-patients-a-randomized-controlled-trial 2024-09-06T08:10:40.229Z daily 0.8 https://larvol.hashnode.dev/phase-i-trial-of-ccl21-modified-dendritic-cells-and-pembrolizumab-in-nsclc-enhancing-antitumor-immunity-in-pd-l1-low-tumors 2024-09-06T08:09:02.025Z daily 0.8 https://larvol.hashnode.dev/phase-ii-trial-of-sta-9090-in-colorectal-cancer-evaluating-efficacy-side-effects-and-molecular-markers 2024-09-06T08:08:04.955Z daily 0.8 https://larvol.hashnode.dev/phase-iii-trial-of-ceritinib-with-brentuximab-vedotin-in-treatment-naive-alk-positive-anaplastic-large-cell-lymphoma-safety-dosage-and-efficacy 2024-09-06T08:06:40.207Z daily 0.8 https://larvol.hashnode.dev/phase-ii-trial-of-fr901228-for-refractory-stomach-or-gastroesophageal-junction-cancer-efficacy-and-safety-evaluation 2024-09-06T08:05:44.605Z daily 0.8 https://larvol.hashnode.dev/archive 2026-10-09T13:48:01.484Z daily 0.5 https://larvol.hashnode.dev/recommendations 2026-10-09T13:48:01.484Z weekly 0.4